Abstract
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
Author contributions
SK: Conceptualization, Methodology, Formal Analysis, Data Curation, Investigation, Writing-Original draft, Writing-Reviewing and Editing; JP: Formal Analysis, Data curation, Investigation, Writing-Original draft, Writing-Reviewing, and Editing; BB: Conceptualization, Data Curation, Writing-Reviewing, and Editing; AV: Conceptualization, Methodology, Data Curation, Writing-Reviewing and Editing, Investigation, Supervision.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
Available on request due to privacy/ethical restrictions.